NCT02992223
Completed
Not Applicable
Retrospective Collection of Data on Patient With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Y90 Ibritumomab Tiuxetan Radioimmunotherapy Plus High-Dose Chemotherapy and Autologous Stem Cell Transplant
A.O.U. Città della Salute e della Scienza0 sites58 target enrollmentJuly 2014
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Refractory B-Cell Non-Hodgkin Lymphoma
- Sponsor
- A.O.U. Città della Salute e della Scienza
- Enrollment
- 58
- Primary Endpoint
- Overall Survival
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
Evaluate if Y90 Ibritumomab Tiuxetan Radioimmunotherapy in addition to standard high dose chemotherapy followed by autologous stem cell transplant could improve prognosis in patients affected by relapsed/refractory aggressive non Hodgkin lymphoma
Investigators
Barbara Botto
MD
A.O.U. Città della Salute e della Scienza
Eligibility Criteria
Inclusion Criteria
- •High Risk Relapsed/refractory aggressive non-hodgkin lymphoma defined as:
- •Progressive disease
- •Early relapse (within 12 months from response)
- •Recurrent relapse
- •Treated with salvage chemotherapy followed by Y90 Ibritumomab Tiuxetan plus high-dose chemotherapy and Autologous stem cell transplant
- •Age \> 18 years
- •Previous treatment with Rituximab
- •Written informed consent
Exclusion Criteria
- •Patient with no complete data available for collection
Outcomes
Primary Outcomes
Overall Survival
Time Frame: Date of last follow-up for at least 18 months (up to 78 months)
Time to last follow-up or death
Progression Free Survival
Time Frame: From first response to last follow-up for at least 18 month (up to 78 months)
Time from last response to nearest relapse or follow-up
Similar Trials
Completed
Not Applicable
Radioimmunotherapy with 90Y Ibritumumab Tiuxetan in B-cell CD20+ indolent non-Hodgkin LymphomaISRCTN36210045Foundation for the Study of hematology in Aragon [Fundación para el Estudio de la Hematologia y Hemoterapia en Aragón](FEHHA)50
Completed
Phase 3
Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line ChemotherapyLymphoma, Non-HodgkinNCT00185393Bayer414
Completed
Phase 1
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative DisorderPost-transplant Lymphoproliferative DisorderRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaStage III Adult Burkitt LymphomaStage III Adult Diffuse Large Cell LymphomaStage IV Adult Burkitt LymphomaStage IV Adult Diffuse Large Cell LymphomaWaldenström MacroglobulinemiaNCT00064246National Cancer Institute (NCI)28
Completed
Phase 2
A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin LymphomasPrimary Non-Hodgkin-LymphomaRefractory Non-Hodgkin-LymphomaCD20+ Aggressive Non-Hodgkin's LymphomaNCT00521560Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH28
Completed
Phase 2
Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaNCT00336843Asan Medical Center19